Your browser doesn't support javascript.
loading
Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors.
Lo Russo, Giuseppe; Pusceddu, Sara; Prinzi, Natalie; Imbimbo, Martina; Proto, Claudia; Signorelli, Diego; Vitali, Milena; Ganzinelli, Monica; Maccauro, Marco; Buzzoni, Roberto; Seregni, Ettore; de Braud, Filippo; Garassino, Marina Chiara.
Afiliación
  • Lo Russo G; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Giacomo Venezian 1, Milan, Italy. giuseppe.lorusso@istitutotumori.mi.it.
  • Pusceddu S; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Giacomo Venezian 1, Milan, Italy.
  • Prinzi N; Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy.
  • Imbimbo M; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Giacomo Venezian 1, Milan, Italy.
  • Proto C; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Giacomo Venezian 1, Milan, Italy.
  • Signorelli D; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Giacomo Venezian 1, Milan, Italy.
  • Vitali M; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Giacomo Venezian 1, Milan, Italy.
  • Ganzinelli M; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Giacomo Venezian 1, Milan, Italy.
  • Maccauro M; Department of Nuclear Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Buzzoni R; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Giacomo Venezian 1, Milan, Italy.
  • Seregni E; Department of Nuclear Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • de Braud F; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, University of Milan, Milan, Italy.
  • Garassino MC; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Giacomo Venezian 1, Milan, Italy.
Tumour Biol ; 37(10): 12991-13003, 2016 Oct.
Article en En | MEDLINE | ID: mdl-27460087
Well-differentiated bronchial neuroendocrine tumors (B-NETs) are rare. They represent 1-5 % of all lung cancers. The incidence of these neoplasms has risen over the past 30 years and, especially for advanced or metastatic disease, management is complex and requires a multidisciplinary approach. Treatment with somatostatin analogs (SSAs) is the most important first-line therapy, in particular in well-differentiated NETs with high somatostatin type receptor (SSTR) expression. In these tumors, the role of mammalian target of rapamycin (m-TOR) inhibitors and the potential utility of other target therapies remain unclear while chemotherapy represents the gold standard treatment only for aggressive forms with low SSTR expression. Peptide receptor radionuclide therapy (PRRT) is an emerging treatment modality for advanced NETs. There are many cumulative evidences about the effectiveness and tolerability of this therapeutic approach, especially in gastro-entero-pancreatic (GEP)-NETs. For B-NETs, scientific research is moving more slowly. Here, we performed a review in order to evaluate the efficacy and toxicity of PRRT with a focus on patients with inoperable or metastatic well-differentiated B-NETs.
Asunto(s)
Palabras clave
Buscar en Google
Bases de datos: MEDLINE Asunto principal: Neoplasias de los Bronquios / Receptores de Somatostatina / Receptores de Péptidos / Tumores Neuroendocrinos / Radiofármacos Límite: Humans Idioma: En Revista: Tumour Biol Asunto de la revista: NEOPLASIAS Año: 2016 Tipo del documento: Article País de afiliación: Italia
Buscar en Google
Bases de datos: MEDLINE Asunto principal: Neoplasias de los Bronquios / Receptores de Somatostatina / Receptores de Péptidos / Tumores Neuroendocrinos / Radiofármacos Límite: Humans Idioma: En Revista: Tumour Biol Asunto de la revista: NEOPLASIAS Año: 2016 Tipo del documento: Article País de afiliación: Italia